Biocon: Biocon Biologics Aims To Grow Its Biosimilar Oncology Offerings

 06 Jan 2026 05:40 PM

Biocon: Biocon Biologics Aims To Grow Its Biosimilar Oncology Offerings

Biocon: Company Issues 2 Billion Rupees in Commercial Papers

 02 Jan 2026 05:41 PM

Biocon: Company Issues 2 Billion Rupees in Commercial Papers

Biocon: Company Partners With Ajanta To Market Semaglutide In 26 Nations

 23 Dec 2025 05:52 PM

Biocon: Company Partners With Ajanta To Market Semaglutide In 26 Nations

Biocon: Company Gains Complete Global Rights To Biosimilar Adalimumab By Expanding FKB In-Licensing Deal; Takes Charge Of Manufacturing And Sales; FKB Will Lower Development Expenses And Earn Royalties.

 23 Dec 2025 09:12 AM

Biocon: Company Gains Complete Global Rights To Biosimilar Adalimumab By Expanding FKB In-Licensing Deal; Takes Charge Of Manufacturing And Sales; FKB Will Lower Development Expenses And Earn Royalties.

Biocon: Company Issues Commercial Papers Worth ₹18 Billion

 22 Dec 2025 07:43 PM

Biocon: Company Issues Commercial Papers Worth ₹18 Billion

Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility

 18 Dec 2025 05:51 PM

Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility

Biocon: Company Launches Liraglutide, A Glucagon-Like Peptide-1, In The Netherland

 15 Dec 2025 08:54 AM

Biocon: Company Launches Liraglutide, A Glucagon-Like Peptide-1, In The Netherland

Biocon: Company Introduces Liraglutide, A Glucagon-Like Peptide-1, In The Netherlands, Marketing It As Diavorin® And Vobexoryn®; This Marks Their First EU Launch Under Their Own Brand After MEB Approval

 15 Dec 2025 08:55 AM

Biocon: Company Introduces Liraglutide, A Glucagon-Like Peptide-1, In The Netherlands, Marketing It As Diavorin® And Vobexoryn®; This Marks Their First EU Launch Under Their Own Brand After MEB Approval

BIOCON: CO. SIGNS SETTLEMENT AND LICENSE AGREEMENT TO COMMERCIALIZE BIOSIMILAR AFLIBERCEPT WORLDWIDE; AGREEMENT CLEARS PATH FOR LAUNCH IN UK JANUARY 2026 AND OTHER COUNTRIES BY MARCH 2026.

 13 Dec 2025 01:46 PM

BIOCON: CO. SIGNS SETTLEMENT AND LICENSE AGREEMENT TO COMMERCIALIZE BIOSIMILAR AFLIBERCEPT WORLDWIDE; AGREEMENT CLEARS PATH FOR LAUNCH IN UK JANUARY 2026 AND OTHER COUNTRIES BY MARCH 2026.

Biocon: Avendus Spark on Biocon maintains 'Add' with Price Target of Rs 435

 08 Dec 2025 09:00 AM

Biocon: Avendus Spark on Biocon maintains 'Add' with Price Target of Rs 435

Biocon: Goldman Sachs on Biocon Neutral, Price Target Rs 375

 08 Dec 2025 09:00 AM

Biocon: Goldman Sachs on Biocon Neutral, Price Target Rs 375

Biocon: BOFA SEC on Biocon Buy, Price Target Rs 455

 08 Dec 2025 09:02 AM

Biocon: BOFA SEC on Biocon Buy, Price Target Rs 455

Biocon: Board Greenlights Fundraising of Up to ₹4,500 Crore Through Various Securities for Cash to Mylan

 06 Dec 2025 03:04 PM

Biocon: Board Greenlights Fundraising of Up to ₹4,500 Crore Through Various Securities for Cash to Mylan

Biocon: Company Gets Tentative FDA Nod For Carbidope And Levodopa Extended-Release Capsules For Parkinson's Disease

 05 Dec 2025 06:21 PM

Biocon: Company Gets Tentative FDA Nod For Carbidope And Levodopa Extended-Release Capsules For Parkinson's Disease

Biocon: Company To Explore Raising Funds Through Commercial Paper Or Issuing Shares on Dec 6

 04 Dec 2025 08:35 AM

Biocon: Company To Explore Raising Funds Through Commercial Paper Or Issuing Shares on Dec 6

Biocon: Plans To Invest In Biocon Biologics By Purchasing Securities From Shareholders On December 6

 04 Dec 2025 08:35 AM

Biocon: Plans To Invest In Biocon Biologics By Purchasing Securities From Shareholders On December 6

Biocon: Company Confirms Launch Date For Denosumab Biosimilars In Europe And Worldwide; Agreement With Amgen Allows For Sales; Vevzuo® And Evfaxy® Set To Release On December 2, 2025

 02 Dec 2025 09:07 AM

Biocon: Company Confirms Launch Date For Denosumab Biosimilars In Europe And Worldwide; Agreement With Amgen Allows For Sales; Vevzuo® And Evfaxy® Set To Release On December 2, 2025

Biocon: Gets USFDA Green Light For Tofacitinib Extended-Release Tablets; Final Approval For 11mg Strength And Tentative Approval For 22mg Strength; Used For Rheumatoid Arthritis And Other Conditions.

 19 Nov 2025 09:09 AM

Biocon: Gets USFDA Green Light For Tofacitinib Extended-Release Tablets; Final Approval For 11mg Strength And Tentative Approval For 22mg Strength; Used For Rheumatoid Arthritis And Other Conditions.

Biocon: Co Managing Director States No Board Action Taken Yet on Biocon Biologics Merger.

 13 Nov 2025 10:22 AM

Biocon: Co Managing Director States No Board Action Taken Yet on Biocon Biologics Merger.

Biocon: Co Management Anticipates Margins of Around 40% from October to March, -Concall Updates

 12 Nov 2025 09:34 AM

Biocon: Co Management Anticipates Margins of Around 40% from October to March, -Concall Updates